RESUMEN
SAR studies on a series of thiophene amide derivatives provided CB(2) receptor agonists. The activity of the compounds was characterized by radioligand binding determination, multiple functional assays, ADME, and pharmacokinetic studies. A representative compound with selectivity for CB(2) over CB(1) effectively produced analgesia in behavioral models of neuropathic, inflammatory, and postsurgical pain. Control experiments using a CB(2) antagonist demonstrated the efficacy in the pain models resulted from CB(2) agonism.
Asunto(s)
Amidas/síntesis química , Analgésicos/síntesis química , Hiperalgesia/tratamiento farmacológico , Neuralgia/tratamiento farmacológico , Receptor Cannabinoide CB2/agonistas , Tiofenos/síntesis química , Amidas/farmacocinética , Amidas/farmacología , Analgésicos/farmacocinética , Analgésicos/farmacología , Animales , Disponibilidad Biológica , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Humanos , Hiperalgesia/metabolismo , Neuralgia/metabolismo , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/metabolismo , Relación Estructura-Actividad , Tiofenos/farmacocinética , Tiofenos/farmacologíaRESUMEN
Several 3-acylindoles with high affinity for the CB(2) cannabinoid receptor and selectivity over the CB(1) receptor have been prepared. A variety of 3-acyl substituents were investigated, and the tetramethylcyclopropyl group was found to lead to high affinity CB(2) agonists (5, 16). Substitution at the N1-indole position was then examined. A series of aminoalkylindoles was prepared and several substituted aminoethyl derivatives were active (23-27, 5) at the CB(2) receptor. A study of N1 nonaromatic side chain variants provided potent agonists at the CB(2) receptor (16, 35-41, 44-47, 49-54, and 57-58). Several polar side chains (alcohols, oxazolidinone) were well-tolerated for CB(2) receptor activity (41, 50), while others (amide, acid) led to weaker or inactive compounds (55 and 56). N1 aromatic side chains also afforded several high affinity CB(2) receptor agonists (61, 63, 65, and 69) but were generally less potent in an in vitro CB(2) functional assay than were nonaromatic side chain analogues.
Asunto(s)
Indoles/farmacología , Cetonas/farmacología , Receptor Cannabinoide CB2/agonistas , Diseño de Fármacos , Humanos , Indoles/síntesis química , Indoles/química , Cetonas/síntesis química , Cetonas/química , Ligandos , Estructura Molecular , Receptor Cannabinoide CB1/agonistas , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
Studies demonstrating the antihyperalgesic and antiallodynic effects of cannabinoid CB(2) receptor activation have been largely derived from the use of receptor-selective ligands. Here, we report the identification of A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], a potent and selective CB(2) agonist as characterized in in vitro pharmacological assays and in in vivo models of pain and central nervous system (CNS) behavior models. In radioligand binding assays, A-836339 displays high affinities at CB(2) receptors and selectivity over CB(1) receptors in both human and rat. Likewise, A-836339 exhibits high potencies at CB(2) and selectivity over CB(1) receptors in recombinant fluorescence imaging plate reader and cyclase functional assays. In addition A-836339 exhibits a profile devoid of significant affinity at other G-protein-coupled receptors and ion channels. A-836339 was characterized extensively in various animal pain models. In the complete Freund's adjuvant model of inflammatory pain, A-836339 exhibits a potent CB(2) receptor-mediated antihyperalgesic effect that is independent of CB(1) or mu-opioid receptors. A-836339 has also demonstrated efficacies in the chronic constrain injury (CCI) model of neuropathic pain, skin incision, and capsaicin-induced secondary mechanical hyperalgesia models. Furthermore, no tolerance was developed in the CCI model after subchronic treatment with A-836339 for 5 days. In assessing CNS effects, A-836339 exhibited a CB(1) receptor-mediated decrease of spontaneous locomotor activities at a higher dose, a finding consistent with the CNS activation pattern observed by pharmacological magnetic resonance imaging. These data demonstrate that A-836339 is a useful tool for use of studying CB(2) receptor pharmacology and for investigation of the role of CB(2) receptor modulation for treatment of pain in preclinical animal models.
Asunto(s)
Amidas/farmacología , Ciclopropanos/farmacología , Inflamación/fisiopatología , Dolor/fisiopatología , Receptor Cannabinoide CB1/fisiología , Receptor Cannabinoide CB2/fisiología , Animales , Células CHO , Línea Celular , Cricetinae , Cricetulus , Procedimientos Quirúrgicos Dermatologicos , Miembro Posterior , Humanos , Hiperalgesia/fisiopatología , Riñón/embriología , Imagen por Resonancia Magnética/métodos , Masculino , Dolor Postoperatorio/fisiopatología , Desempeño Psicomotor/efectos de los fármacos , Desempeño Psicomotor/fisiología , Ratas , Ratas Sprague-Dawley , Receptor Cannabinoide CB2/agonistasRESUMEN
Cannabinoid CB(2) receptors may couple to a variety of G proteins and intracellular effector systems to regulate physiological and pathophysiological processes involved in inflammatory and neuropathic pain. In this study, the coupling of cannabinoid hCB(2) receptors to Galpha(qo5) and Galpha(qi5) proteins was studied and compared by investigating the pharmacological properties of HEK-293 cells co-expressing cannabinoid hCB(2) with chimeric Galpha(qo5) (HEK-hCB(2)-G(qo5)) or Galpha(qi5) (HEK-hCB(2)-G(qi5)). Both cell lines were found to be amendable for measuring cannabinoid CB(2) receptor agonist evoked Ca(2+) mobilization in a high-throughput manner. Comparison of binding affinities of ligands in homogenates prepared from both cell lines revealed similar affinities for [(3)H]CP55,940 displacement with the following rank order: CP55,940 approximately WIN55,212-2 > SR144528 > JWH015approximatelyAM1241approximately AM630 > SR141617A approximately AM251. In comparison at cannabinoid hCB(1) receptors: the rank order was: SR141617A approximately CP55,940 > AM251 > WIN55,212-2 > AM1241approximatelySR144528 > JWH015approximatelyAM630. No significant differences in cannabinoid receptor agonist (CP55,940 approximately WIN55,212-2 > JWH015) or antagonist(SR144528 approximately AM1241 > AM630 > AM251 approximately SR141617A) profiles were observed in HEK-hCB(2)-G(qo5) and HEK-hCB(2)-G(qi5) cells as determined using intracellular Ca(2+) measurements. Experiments with HEK-hCB(2)-G(qi5) cells carried out by investigating interactions among CP55,940, carbachol, thapsigargin, and U73122 revealed that the mechanism of cannabinoid hCB(2) receptor coupling via chimeric G proteins to Ca(2+) mobilization involves phospholipase C-inositol trisphosphate (PLC-IP(3)) and that it is less efficient in comparison to the endogenous muscarinic mediated PLC-IP(3)-Ca(2+) pathway. This study demonstrates that expressed cannabinoid CB(2) receptors couple equally well to Galpha(qo5) and Galpha(qi5) proteins and that receptor agonist or antagonist pharmacology is not influenced by the nature of these coupled G proteins when heterologously expressed.
Asunto(s)
Subunidades alfa de la Proteína de Unión al GTP Gq-G11/metabolismo , Receptor Cannabinoide CB2/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Animales , Calcio/metabolismo , Línea Celular , Expresión Génica , Humanos , Fosfatos de Inositol/metabolismo , Espacio Intracelular/efectos de los fármacos , Espacio Intracelular/metabolismo , Ligandos , Fosfolipasas/metabolismo , Receptor Cannabinoide CB2/agonistas , Receptor Cannabinoide CB2/antagonistas & inhibidores , Receptores Muscarínicos/metabolismo , Transducción de SeñalRESUMEN
A series of potent indol-3-yl-tetramethylcyclopropyl ketones have been prepared as CB 2 cannabinoid receptor ligands. Two unsubstituted indoles ( 5, 32) were the starting points for an investigation of the effect of indole ring substitutions on CB 2 and CB 1 binding affinities and activity in a CB 2 in vitro functional assay. Indole ring substitutions had varying effects on CB 2 and CB 1 binding, but were generally detrimental to agonist activity. Substitution on the indole ring did lead to improved CB 2/CB 1 binding selectivity in some cases (i.e., 7- 9, 15- 20). All indoles with the morpholino-ethyl side chain ( 32- 43) exhibited weaker binding affinity and less agonist activity relative to that of their tetrahydropyranyl-methyl analogs ( 5- 31). Several agonists were active in the complete Freund's adjuvant model of chronic inflammatory thermal hyperalgesia ( 32, 15).
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Indoles/farmacología , Cetonas/farmacología , Receptor Cannabinoide CB2/efectos de los fármacos , Animales , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/química , Unión Competitiva , Línea Celular , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Hiperalgesia/inducido químicamente , Hiperalgesia/tratamiento farmacológico , Indoles/síntesis química , Indoles/química , Cetonas/síntesis química , Cetonas/química , Ligandos , Conformación Molecular , Ratas , Receptor Cannabinoide CB1/efectos de los fármacos , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
PURPOSE: The objective of this study was to characterize the antiseizure and safety profiles of ABT-769 [(R)-N-(2 amino-2-oxoethyl)spiro[2,5]octane-1-carboxamide]. METHODS: ABT-769 was tested for protection against maximal electroshock and pentylenetetrazol-induced seizures in the mouse and for suppression of electrically kindled amygdala seizures and spontaneous absence-like seizures in the rat. The central nervous system safety profile was evaluated by using tests of motor coordination and inhibitory avoidance. The potential for liver toxicity was assessed in vitro by using a mitochondrial fatty acid beta-oxidation assay. Teratogenic potential was assessed in the mouse. RESULTS: ABT-769 blocked maximal electroshock, subcutaneous pentylenetetrazol and intravenous pentylenetetrazol-induced seizures with median effective dose (ED50) values of 0.25, 0.38, and 0.11 mmol/kg, p.o., respectively. No tolerance was evident in the intravenous pentylenetetrazol test after twice-daily dosing of ABT-769 (0.3 mmol/kg, p.o.) for 4 days. ABT-769 blocked absence-like spike-wave discharge (ED50, 0.15 mmol/kg, p.o.) and shortened the cortical and amygdala afterdischarge duration of kindled seizures (1 and 3 mmol/kg, p.o.). The protective indices (ED50 rotorod impairment/ED50 seizure protection) were 4.8, 3.2, and 10.9 in the maximal electroshock, subcutaneous pentylenetetrazol and intravenous pentylenetetrazol seizure tests, respectively. ABT-769 did not affect inhibitory avoidance performance (0.1-1 mmol/kg, p.o.). ABT-769 did not affect mitochondrial fatty acid beta-oxidation or induce neural tube defects. CONCLUSIONS: ABT-769 is an efficacious antiseizure agent in animal models of convulsive and nonconvulsive epilepsy and has a favorable safety profile. ABT-769 has a broad-spectrum profile like that of valproic acid. Its profile is clearly different from those of carbamazepine, phenytoin, lamotrigine, topiramate, vigabatrin, and tiagabine.